No Data
No Data
No Data
PSYENCE GROUP INC To Carry Out 1-for-15 Reverse Stock Split On April 23rd, 2025
Psyence Group Announces Share Consolidation
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners With Fluence and INGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
Press Release: Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study
Psyence Biomedical Ltd. Approved to List on Nasdaq Following Completion of Business Combination Agreement With Newcourt Acquisition Corp